142801-55-6

Basic information

• Product Name: Carbamic acid, [(1S)-4-[[imino[[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]methyl] amino]-1-[(methoxymethylamino)carbonyl]butyl]-, 1,1-dimethylethyl ester
• CAS NO: 142801-55-6
• Molecular Formula: C23H39N5O7S
• Molecular Weight: 529.658
• Mol File: 142801-55-6.mol
• Article Data: 13

Chemical Properties

• CAS DataBase Reference: Carbamic acid, [(1S)-4-[[imino[[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]methyl] amino]-1-[(methoxymethylamino)carbonyl]butyl]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [(1S)-4-[[imino[[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]methyl] amino]-1-[(methoxymethylamino)carbonyl]butyl]-, 1,1-dimethylethyl ester(142801-55-6)
• EPA Substance Registry System: Carbamic acid, [(1S)-4-[[imino[[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]methyl] amino]-1-[(methoxymethylamino)carbonyl]butyl]-, 1,1-dimethylethyl ester(142801-55-6)

Safety Data

• Hazardous Substances Data: 142801-55-6(Hazardous Substances Data)

Upstream product

• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 102185-38-6 Nα-(t-butyloxycarbonyl)-Nω-(4-methoxy-2,3,6-trimethylbenzenesulphonyl)-L-arginine 
• 1117-97-1 N,0-dimethylhydroxylamine 

Downstream Products

• 183442-79-7 [(S)-4-{[[(Z)-tert-Butoxycarbonylimino]-(4-methoxy-2,3,6-trimethyl-benzenesulfonylamino)-methyl]-amino}-1-(methoxy-methyl-carbamoyl)-butyl]-carbamic acid tert-butyl ester 
• 201006-62-4 [(1S)-1-(2-benzothiazolylcarbonyl)-4-[[imino[[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]methyl]amino]butyl]carbamic acid 1,1-dimethylethyl ester 
• 203453-39-8 N-<4-amino-5-(1,3-benzothiazol-2-yl)-5-hydroxypentyl>-N'-<(4-methoxy-2,3,6-trimethylphenyl)sulfonyl>guanidine 
• 287182-91-6 C₂₈H₃₉N₅O₆S₂ 
• 287183-01-1 C₃₀H₄₀N₆O₇S₂ 

Relevant articles and documents

Analysis of subpocket selectivity and identification of potent selective inhibitors for matriptase and matriptase-2

We studied the factors affecting the selectivity of peptidomimetic inhibitors of the highly homologous proteases matriptase and matriptase-2 across subpockets using docking simulations. We observed that the farther away a subpocket is located from the catalytic site, the more pronounced its role in selectivity. As a result of our exhaustive virtual screening, we biochemically validated novel potent and selective inhibitors of both enzymes.

Discovery of Selective Matriptase and Hepsin Serine Protease Inhibitors: Useful Chemical Tools for Cancer Cell Biology

Matriptase and hepsin belong to the family of type II transmembrane serine proteases (TTSPs). Increased activity of these and the plasma protease, hepatocyte growth factor activator (HGFA), is associated with unregulated cell signaling and tumor progression through increased MET and RON kinase signaling pathways. These proteases are highly expressed in multiple solid tumors and hematological malignancies. Herein, we detail the synthesis and structure-activity relationships (SAR) of a dipeptide library bearing Arg α-ketobenozothiazole (kbt) warheads as novel inhibitors of HGFA, matriptase, and hepsin. We elucidated the substrate specificity for HGFA using positional scanning of substrate combinatorial libraries (PS-SCL), which was used to discover selective inhibitors of matriptase and hepsin. Using these selective inhibitors, we have clarified the specific role of hepsin in maintaining epithelial cell membrane integrity, known to be lost in breast cancer progression. These selective compounds are useful as chemical biology tools and for future drug discovery efforts.

MATRIPTASE INHIBITORS AND USES THEREOF AGAINST ORTHOMYXOVIRIDAE INFECTIONS

The present invention provides matriptase inhibitors and compositions for treating and preventing orthomyxovirus infections such as flu infections. The present invention also provides novel compounds, compositions, methods of use, uses and kits thereof for inhibiting matriptase. Such compounds are useful for treating and preventing orthomyxovirus infections, such as flu infections, and for inhibiting tumor growth, progression and/or metastasis.